These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 25612847)

  • 1. Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma.
    Castillo JJ; Reagan JL; Sikov WM; Winer ES
    Br J Haematol; 2015 May; 169(3):352-5. PubMed ID: 25612847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.
    Purroy N; Bergua J; Gallur L; Prieto J; Lopez LA; Sancho JM; García-Marco JA; Castellví J; Montes-Moreno S; Batlle A; de Villambrosia SG; Carnicero F; Ferrando-Lamana L; Piris MA; Lopez A
    Br J Haematol; 2015 Apr; 169(2):188-98. PubMed ID: 25521006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma.
    Furman RR; Martin P; Ruan J; Cheung YK; Vose JM; LaCasce AS; Elstrom R; Coleman M; Leonard JP
    Cancer; 2010 Dec; 116(23):5432-9. PubMed ID: 20665890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas.
    Sinha R; Kaufman JL; Khoury HJ; King N; Shenoy PJ; Lewis C; Bumpers K; Hutchison-Rzepka A; Tighiouart M; Heffner LT; Lechowicz MJ; Lonial S; Flowers CR
    Cancer; 2012 Jul; 118(14):3538-48. PubMed ID: 22535574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.
    Ruan J; Martin P; Furman RR; Lee SM; Cheung K; Vose JM; Lacasce A; Morrison J; Elstrom R; Ely S; Chadburn A; Cesarman E; Coleman M; Leonard JP
    J Clin Oncol; 2011 Feb; 29(6):690-7. PubMed ID: 21189393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasmablastic lymphoma - single centre experience with infusional EPOCH chemotherapy.
    Jayachandran PK; Rajan AK; Karunakaran P; Mehra N; Selvarajan G; Kesana S; Dhanushkodi M; Radhakrishnan V; Sagar TG
    Leuk Res; 2020 Aug; 95():106391. PubMed ID: 32559556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study.
    García-Suárez J; Bañas H; Arribas I; De Miguel D; Pascual T; Burgaleta C
    Br J Haematol; 2007 Jan; 136(2):276-85. PubMed ID: 17233819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA).
    Ribrag V; Gisselbrecht C; Haioun C; Salles G; Golfier JB; Ertault M; Ferme C; Briere J; Brice P; Mounier N
    Cancer; 2009 Oct; 115(19):4540-6. PubMed ID: 19593797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib-contained chemotherapy and thalidomide combined with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) play promising roles in plasmablastic lymphoma: a case report and literature review.
    Cao C; Liu T; Zhu H; Wang L; Kai S; Xiang B
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):e145-50. PubMed ID: 25225082
    [No Abstract]   [Full Text] [Related]  

  • 10. A multicenter trial of infusional etoposide, doxorubicin, and vincristine with cyclophosphamide and prednisone (EPOCH) in patients with relapsed non-Hodgkin's lymphoma.
    Wilder DD; Ogden JL; Jain VK
    Clin Lymphoma; 2001 Mar; 1(4):285-92. PubMed ID: 11707843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD20-positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximab.
    Yan M; Dong Z; Zhao F; Chauncey T; Deauna-Limayo D; Wang-Rodriguez J; Liu D; Wang HY; Pilz R
    Eur J Haematol; 2014 Jul; 93(1):77-80. PubMed ID: 24528507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis.
    Dittus C; Grover N; Ellsworth S; Tan X; Park SI
    Leuk Lymphoma; 2018 Sep; 59(9):2121-2127. PubMed ID: 29303024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of constitutively activated NF-κB/mTORC pathway proteins and response to CHOP with bortezomib in a patient with angioimmunoblastic peripheral T-cell lymphoma.
    Quesada AE; Rios A; Brown RE; Nguyen ND
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S87-9. PubMed ID: 25486962
    [No Abstract]   [Full Text] [Related]  

  • 14. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.
    Robak T; Huang H; Jin J; Zhu J; Liu T; Samoilova O; Pylypenko H; Verhoef G; Siritanaratkul N; Osmanov E; Alexeeva J; Pereira J; Drach J; Mayer J; Hong X; Okamoto R; Pei L; Rooney B; van de Velde H; Cavalli F;
    N Engl J Med; 2015 Mar; 372(10):944-53. PubMed ID: 25738670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Advanced AIDS Patient With CD4 <20 and Plasmablastic Lymphoma Achieving Complete Response With the V-EPOCH Regimen.
    Nelson B; Hong A; Iqbal F; Venkatesan R
    Cureus; 2020 Jun; 12(6):e8641. PubMed ID: 32685310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous plasmablastic lymphoma.
    Jambusaria A; Shafer D; Wu H; Al-Saleem T; Perlis C
    J Am Acad Dermatol; 2008 Apr; 58(4):676-8. PubMed ID: 18342714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma.
    Furtado M; Johnson R; Kruger A; Turner D; Rule S
    Br J Haematol; 2015 Jan; 168(1):55-62. PubMed ID: 25146720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management.
    Ramirez-Gamero A; Martínez-Cordero H; Beltrán BE; Florindez J; Malpica L; Castillo JJ
    Am J Hematol; 2024 Aug; 99(8):1586-1594. PubMed ID: 38767403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary bone marrow diffuse large B-cell lymphoma affecting distal parts of the legs as a cause of persisting B symptoms.
    Lapa C; Knott M; Rasche L; Herrmann K; Buck AK; Rosenwald A
    Eur J Haematol; 2014 Dec; 93(6):545-6. PubMed ID: 24612353
    [No Abstract]   [Full Text] [Related]  

  • 20. Orbital plasmablastic lymphoma--comparison of a newly reported entity with diffuse large B-cell lymphoma of the orbit.
    Morley AM; Verity DH; Meligonis G; Rose GE
    Orbit; 2009; 28(6):425-9. PubMed ID: 19929677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.